{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:54:02Z","timestamp":1783000442910,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00415-018-8996-3","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T08:54:22Z","timestamp":1534236862000},"page":"2342-2345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients"],"prefix":"10.1007","volume":"265","author":[{"given":"Ursela","family":"Baber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bouley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Egnor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Sloane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,14]]},"reference":[{"issue":"1","key":"8996_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","volume":"9","author":"HM G\u00fcrcan","year":"2009","unstructured":"G\u00fcrcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9(1):10\u201325","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"8996_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/archneur.62.2.258","volume":"62","author":"NL Monson","year":"2005","unstructured":"Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62(2):258\u2013264","journal-title":"Arch Neurol"},{"key":"8996_CR3","first-page":"84","volume":"13","author":"M Duddy","year":"2006","unstructured":"Duddy M, Bar-Or A (2006) B-cells in multiple sclerosis. Int MS J 13:84\u201390","journal-title":"Int MS J"},{"issue":"7","key":"8996_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676\u2013688","journal-title":"N Engl J Med"},{"issue":"3","key":"8996_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234","journal-title":"N Engl J Med"},{"issue":"3","key":"8996_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209\u2013220","journal-title":"N Engl J Med"},{"issue":"9","key":"8996_CR7","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, Perry A, Yerra R, Schmidt R, Alvarez E, Tyler KL (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68(9):1156\u20131164","journal-title":"Arch Neurol"},{"issue":"4","key":"8996_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9(4):425\u2013437","journal-title":"Lancet Neurol"},{"key":"8996_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fimmu.2018.00138","volume":"9","author":"EA Mills","year":"2018","unstructured":"Mills EA, Mao-Draayer Y (2018) Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: A bird\u2019s eye view. Front Immunol 9:138","journal-title":"Front Immunol"},{"issue":"22","key":"8996_CR10","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","volume":"78","author":"AK Trampe","year":"2012","unstructured":"Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A (2012) Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 78(22):1736\u20131742","journal-title":"Neurology"},{"key":"8996_CR11","unstructured":"Friedman-Urevich S, Gottesman M, Farley S (2017) Longitudinal changes in jcv titers in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate. Abstract, CMSC New Orleans"},{"issue":"14","key":"8996_CR12","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1177\/1352458515599681","volume":"21","author":"J Raffel","year":"2015","unstructured":"Raffel J, Gafson AR, Malik O, Nicholas R (2015) Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler 21(14):1833\u20131838","journal-title":"Mult Scler"},{"key":"8996_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne D, Burns S.,Jayne D (2015) Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 57:60\u201365","journal-title":"J Autoimmun"},{"issue":"9","key":"8996_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, Yun S, Joo J, Kim HJ (2015) Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72(9):989\u2013995","journal-title":"JAMA Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-8996-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8996-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8996-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T23:10:50Z","timestamp":1565737850000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-8996-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,14]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["8996"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-8996-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,14]]},"assertion":[{"value":"20 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"UB, AB, and EE have no conflict of interest to declare. JAS has served as a consultant for Biogen, Serono, Genzyme, Genetech, and Teva. JAS has grant funding from Biogen and Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}